CureVac expands therapeutic reach

CureVac AG has expanded its therapeutic reach to include projects targeting genetic diseases in addition to its portfolio of candidate drugs for cancer and infectious disease. This follows an agreement with Arcturus Therapeutics Ltd to develop a product to treat ornithine transcarbamylase (OTC) deficiency.

Full text available to subscribers only. Click here for information on subscribing to MedNous.